BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1539 related articles for article (PubMed ID: 17159189)

  • 1. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
    Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF; ;
    J Clin Oncol; 2007 Jan; 25(1):118-45. PubMed ID: 17159189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
    Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF;
    Arch Pathol Lab Med; 2007; 131(1):18-43. PubMed ID: 19548375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
    J Clin Oncol; 2013 Nov; 31(31):3997-4013. PubMed ID: 24101045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
    Arch Pathol Lab Med; 2014 Feb; 138(2):241-56. PubMed ID: 24099077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    Wolff AC; Hammond MEH; Allison KH; Harvey BE; Mangu PB; Bartlett JMS; Bilous M; Ellis IO; Fitzgibbons P; Hanna W; Jenkins RB; Press MF; Spears PA; Vance GH; Viale G; McShane LM; Dowsett M
    Arch Pathol Lab Med; 2018 Nov; 142(11):1364-1382. PubMed ID: 29846104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    Wolff AC; Hammond MEH; Allison KH; Harvey BE; Mangu PB; Bartlett JMS; Bilous M; Ellis IO; Fitzgibbons P; Hanna W; Jenkins RB; Press MF; Spears PA; Vance GH; Viale G; McShane LM; Dowsett M
    J Clin Oncol; 2018 Jul; 36(20):2105-2122. PubMed ID: 29846122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Performance of Breast Cancer Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization and Brightfield In Situ Hybridization on College of American Pathologists Proficiency Tests.
    Geiersbach KB; Bridge JA; Dolan M; Jennings LJ; Persons DL; Souers RJ; Tsuchiya KD; Vasalos PH; Moncur JT
    Arch Pathol Lab Med; 2018 Oct; 142(10):1254-1259. PubMed ID: 29733681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
    Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
    Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
    Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
    Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
    Press MF; Sauter G; Buyse M; Fourmanoir H; Quinaux E; Tsao-Wei DD; Eiermann W; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Mackey JR; Bee V; Ma Y; Villalobos I; Campeau A; Mirlacher M; Lindsay MA; Slamon DJ
    J Clin Oncol; 2016 Oct; 34(29):3518-3528. PubMed ID: 27573653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
    Xu FP; Wang K; Xu J; Chen J; Zhang YF; Wu HM; Zhang MH; Long XX; Luo XL; Zhang KP; Lin DY; Liu YH
    Breast Cancer Res Treat; 2017 Dec; 166(3):757-764. PubMed ID: 28861637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories.
    Nakhleh RE; Grimm EE; Idowu MO; Souers RJ; Fitzgibbons PL
    Arch Pathol Lab Med; 2010 May; 134(5):728-34. PubMed ID: 20441503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
    Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
    Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.